T

The Center for Clinical Trials | Saraland, AL

Research site

(Unclaimed)

Location

1008 Shelton Beach Road, Saraland, Alabama, United States of America

Site insights

Top conditions

Top treatments

Empagliflozin

Linaclotide

Iron

Inclisiran

Obicetrapib

SAR443765

Lunsekimig

Centanafadine

Loperamide

CIN-102

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 13 total trials

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Active, not recruiting

Primary Prevention of Atherosclerotic Cardiovascular Disease

Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

Drug: Placebo in 1.5ml

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopa...

Enrolling

Idiopathic Gastroparesis

Drug: Placebo

Drug: CIN-102 Dose 15mg

A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD).

To evaluate long-term safety exposure

Active, not recruiting

Attention Deficit/Hyperactivity Disorder

Drug: Centanafadine Hydrochloride

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Enrolling

Attention-Deficit/Hyperactivity Disorder

Drug: Placebo

Drug: 100mg SPN-812

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (AIRLYMPUS)

This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma.The purpose of this study is...

Enrolling

Asthma

Drug: Short-Acting Beta Agonists (SABA)

Drug: Fluticasone/salmeterol